publicEuropean Medicines Agency · European Union · Updated Aug 26, 2026
Orphan Designation Granted for Daratumumab for AL Amyloidosis
Regulatory requirements for daratumumab will need to be reviewed in light of the orphan designation status granted by the EMA.
Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward